File(s) not publicly available
Excretion of sodium 2-mercaptoethanesulphonate (MESNA) in the urine of volunteers after oral dosing
journal contribution
posted on 2023-06-08, 19:54 authored by M S Jones, Ruth Murrell-LagnadoRuth Murrell-Lagnado, I C ShawSodium 2-mercaptoethanesulphonate (MESNA) is a uroprotective agent generally given i.v. to prevent haemorrhagic cystitis during oxazaphosphorine cancer chemotherapy. Oral administration of the drug is described since this might be an important route during long-term oxazaphosphorine treatment. MESNA is absorbed from the GI tract and excreted in the urine (about 41.5% of the dose), peak excretion being 2-3 hr after administration. A proportion of the excreted dose is as free thiols (about 24.2%) and the remainder is as disulphides. MESNA is shown to enhance excretion of cysteine in urine.
History
Publication status
- Published
Journal
European Journal of Cancer and Clinical OncologyISSN
0277-5379Publisher
ElsevierExternal DOI
Issue
5Volume
21Page range
553-555Department affiliated with
- Biochemistry Publications
Full text available
- No
Peer reviewed?
- Yes
Legacy Posted Date
2015-03-25Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC